Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Cytochrome P450 family protein | 0.0097 | 0.5071 | 0.4592 |
Mycobacterium tuberculosis | Possible cytochrome P450 135B1 Cyp135B1 | 0.0053 | 0.0886 | 0.5 |
Leishmania major | cytochrome p450-like protein | 0.0097 | 0.5071 | 1 |
Mycobacterium tuberculosis | Possible cytochrome P450 135A1 Cyp135A1 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 144 Cyp144 | 0.0053 | 0.0886 | 0.5 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0097 | 0.5071 | 1 |
Mycobacterium tuberculosis | Cytochrome P450 51 Cyp51 (CYPL1) (P450-L1A1) (sterol 14-alpha demethylase) (lanosterol 14-alpha demethylase) (P450-14DM) | 0.0053 | 0.0886 | 0.5 |
Loa Loa (eye worm) | CYP4Cod1 | 0.0097 | 0.5071 | 0.5071 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.9548 | 0.9504 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0053 | 0.0886 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.9548 | 0.9548 |
Toxoplasma gondii | cytochrome p450 superfamily protein | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 monooxygenase 142 Cyp142 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 123 Cyp123 | 0.0053 | 0.0886 | 0.5 |
Schistosoma mansoni | cytochrome P450 | 0.0053 | 0.0886 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0097 | 0.5071 | 0.5071 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0097 | 0.5071 | 0.5071 |
Mycobacterium tuberculosis | Probable cytochrome P450 132 Cyp132 | 0.0053 | 0.0886 | 0.5 |
Echinococcus granulosus | cytochrome P450 2K1 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 141 Cyp141 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 130 Cyp130 | 0.0053 | 0.0886 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.9548 | 0.9548 |
Mycobacterium tuberculosis | Probable cytochrome P450 143 Cyp143 | 0.0053 | 0.0886 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 | 0.0053 | 0.0886 | 0.0886 |
Mycobacterium tuberculosis | Probable cytochrome P450 125 Cyp125 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0097 | 0.5071 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0097 | 0.5071 | 0.4592 |
Mycobacterium tuberculosis | Probable cytochrome P450 124 Cyp124 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 140 Cyp140 | 0.0053 | 0.0886 | 0.5 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0097 | 0.5071 | 1 |
Mycobacterium tuberculosis | Probable cytochrome P450 128 Cyp128 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Cytochrome P450 121 Cyp121 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 139 Cyp139 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium leprae | putative cytochrome p450 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Probable cytochrome P450 138 Cyp138 | 0.0053 | 0.0886 | 0.5 |
Trypanosoma brucei | cytochrome P450, putative | 0.0097 | 0.5071 | 1 |
Echinococcus multilocularis | 0.0053 | 0.0886 | 0.5 | |
Mycobacterium tuberculosis | Probable cytochrome P450 137 Cyp137 | 0.0053 | 0.0886 | 0.5 |
Mycobacterium tuberculosis | Possible cytochrome P450 126 Cyp126 | 0.0053 | 0.0886 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0053 | 0.0886 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 14.1254 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 22.3872 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 25.929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.